DRugwatch BlogRSS 2.0

DRugwatch Blog > June 2010 > ASCO 2010: Emerging agents to change the landscape of ovarian cancer treatment

ASCO 2010: Emerging agents to change the landscape of ovarian cancer treatment

Kiran MeekingsWritten by: Kiran Meekings

SUMMARY
With few treatment options and a poor prognosis, ovarian cancer represents a considerable opportunity for drug developers. Currently available chemotherapeutic agents have little impact on improving the prognosis of patients whilst ovarian cancer is one of the few indications with no approved targeted therapies.  However, this may be set to change following the presentation of positive clinical trial results at ASCO.  We anticipate Roche’s Avastin will be approved for the first-line ovarian cancer setting in 2011, adding $1bn to the drug’s sales, whilst encouraging results of Amgen’s AMG386, Eisai’s farletuzumab, AstraZeneca’s olaparib and Sunesis’ voreloxin call for further development.  If the early-stage promise of these first-in-class compounds is substantiated in Phase III, we would anticipate the ovarian cancer market expanding significantly during our forecast period.

ANALYSIS
  • The much-awaited results of Avastin in ovarian cancer were presented yesterday in the plenary session at ASCO.  The results demonstrated that treatment of newly-diagnosed ovarian cancer with chemotherapy and Avastin, followed by maintenance Avastin, significantly improved progression-free survival (PFS): The risk of progression decreased by 28% compared to chemotherapy alone.
  • We anticipate these results will pave the way for approval of Avastin in both the US and EU for induction and maintenance use in the newly diagnosed ovarian cancer population.  We expect that approval in this setting will add nearly $1bn in sales in 2016.
  • Phase II results of Amgen’s first-in-class Ang1 and Ang 2-inhibiting peptibody, AMG386, were presented today, Monday, at ASCO.  Angiopoietin molecules are known to interact with Tie2 and are pivotal players in the angiogenic process.  Thus, inhibition of the angiopoietin-Tie2 interaction may be a new strategy in the fight against metastatic cancer.
  • The results showed that AMG 386 combined with weekly paclitaxel was highly efficacious and tolerable, with a manageable safety profile.  PFS, the primary endpoint, significantly increased from 4.6 months with placebo to 7.2 months in the high-dose AMG 386 arm, suggesting further development of the compound was warranted.  Phase III trials are in planning.
  • Final Phase II data of farletuzumab in platinum-sensitive relapsed ovarian cancer were also presented.  Farletuzumab is an antibody against folate receptor alpha, which is over-expressed in approximately 90% of ovarian cancers. The Phase II trial involved treating patients with both monotherapy and combination farletuzumab.  There was a marked response to the drug, with 89% of patients exhibiting normalization of their CA-125 levels and an overall response rate (ORR) of 70%.  The compound is currently being investigated in Phase III trials in the same setting.
  • PARP inhibitors have been touted for their potential in BRCA-mutated and serous ovarian cancer.  However, all studies to-date have only shown an effect when combined with chemotherapy.  However, results presented at ASCO on Saturday demonstrated that monotherapy olaparib is also an active therapy in high-grade serous ovarian cancer, regardless of BRCA mutation status.  This was shown not to be the case in breast cancer, where monotherapy olaparib did not exert an efficacious effect.  This positive result has the potential to expand the PARP inhibitor market and provide another treatment option for ovarian cancer patients.
  • Lastly, positive data was also reported for the first-in-class quinolone derivative voreloxin in platinum-resistant ovarian cancer.  The ORR of 11%, 12 week disease control rate of 48% and PFS of 84 days was in line with results produced by pegylated liposomal doxorubicin in the same setting.  Adverse events were manageable although a 9% rate of febrile neutropenia will require careful monitoring of patients.  However, the great unmet need in this population of patients and encouraging efficacy data encourages further development.

Posted on: 6/8/2010 1:24:45 PM | with 0 comments


Tags: Conference Commentary, Kiran Meekings, Oncology

Trackback URL: http://decisionresources.com/trackback/b1b5e3f5-ae20-4281-9e40-1cae93dd27e2/ASCO-2010--Emerging-agents-to-change-the-landscape-of-ovarian-cancer-treatment.aspx?culture=en-US

Comments
Blog post currently doesn't have any comments.
Leave comment Subscribe



What is the abbreviation for Accountable Care Organization?

 

rss twitter linkedin

 

DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
2015 ESC Congress in London – Overview of Upcoming Hot Line Sessions
Post date:
7/2/2015 11:57:46 PM
Post Summary:
Conor WalshContributor: Conor Walsh M.Sc., Ph.D.
Topics: Conference Commentary, Cardiovascular

This year’s ESC congress will take place in the Excel Exhibition Centre in London, United Kingdom. The spotlight this year is “environment and the heart,” highlighting the many different kinds of interactions between the environment and cardiovascular diseases.

Post title:
FDA Approval for The Medicines Company’s Intravenous Antiplatelet Kengreal
Post date:
6/23/2015 1:22:54 PM
Post Summary:
Conor WalshContributors: Conor Walsh, M.Sc., Ph.D.
Topics: Cardiovascular

On June 22nd, 2015 the U.S. FDA approved Kengreal (cangrelor), the Medicines Company’s intravenous antiplatelet drug for use “as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.”

Post title:
Hematological Malignancies: Are Immune Checkpoint Inhibitors Checking-in?
Post date:
6/17/2015 9:32:42 AM
Post Summary:
Contributor: Dana Gheorghe, Ph.D
Topics
: Conference Commentary, Oncology


Recent years have seen an added emphasis on the relationship between cancer and the activity of the immune system. Novel agents that aim to harness the immune system have already been approved in the U.S. for solid tumors (Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo [nivolumab] for NSCLC and malignant melanoma, and Merck & Co.’s Keytruda [pembrolizumab] for malignant melanoma), and are in development for a plethora of other oncology indications. Most of the development has been targeted towards solid tumors, but the potential of immune checkpoint inhibitors in hematological malignancies is becoming increasingly evident.

Post title:
Cardiovascular Outcomes Trials Answer Long-Asked Questions – But New Questions Arise
Post date:
6/12/2015 10:26:05 AM
Post Summary:
Contributor: Eamonn O'Connor, Ph.D.

The recent American Diabetes Association’s 75th Scientific Sessions in Boston saw the release of data from the ELIXA cardiovascular outcomes trial (CVOT) for lixisenatide (Sanofi/Zealand Pharma’s Lyxumia), the first such trial completed for the GLP-1 receptor agonist drug class. However, it was the publication of the data from the CVOT for sitagliptin (Merck’s Januvia/Ono’s Glactiv), known as TECOS1, that was most eagerly anticipated; this is because the previous CVOTs for saxagliptin (AstraZeneca’s Onglyza) and alogliptin (Takeda/Furiex’s Nesina/Vipidia) had raised significant concerns about a potential risk for increased rates of hospitalization due to heart failure. The results from TECOS therefore, were viewed as pivotal as to whether this risk was a feature specific to the DPP-IV inhibitor drug class.

Post title:
Malignant Melanoma: Evolving Standards of Care
Post date:
6/5/2015 2:52:20 PM
Post Summary:
Contributor: Natalia Reoutova, M.Sc.
Topics: Conference Commentary, Oncology

The past five years have seen unprecedented progress in the treatment of malignant melanoma, which translated into approval of highly efficacious immunotherapies, targeted small-molecule therapies, and several combination regimens.

Decision Resources Group brands include: